BRIEF-Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury
April 12 Neuralstem Inc
* Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury
* Neuralstem - New cohort of four patients will be added to ongoing phase 1 human clinical trial for NSI-566 spinal cord-derived neural stem cells
* Neuralstem - Amended protocol was approved by U.S. Food and Drug Administration, institutional review board at study site, University of California San Diego Source text for Eikon: Further company coverage:
Gunman in California UPS shooting targeted co-workers for slayings
June 23 The UPS employee who shot three coworkers to death last week inside a United Parcel Service facility in San Francisco before killing himself appears to have singled out his victims deliberately, but a motive remains unknown, police said on Friday.
CORRECTED-UPDATE 2-U.S. to seek to block DraftKings, FanDuel fantasy sports merger
WASHINGTON, June 19 The U.S. Federal Trade Commission said on Monday it will seek to stop the merger of DraftKings and FanDuel, because the combined company would control more than 90 percent of the U.S. market for paid daily fantasy sports contests.